Description
Truqap (capivasertib) is an AKT inhibitor used with fulvestrant for HR+/HER2- advanced breast cancer with specific alterations.
$9,501.30
AKT inhibitor for breast cancer
Truqap (capivasertib) is an AKT inhibitor used with fulvestrant for HR+/HER2- advanced breast cancer with specific alterations.
Reviews
There are no reviews yet.